Govt to do nationwide survey for dengue epidemiology

Image
Press Trust of India New Delhi
Last Updated : Feb 07 2017 | 9:28 PM IST
The government will soon begin a nationwide dengue prevalence survey to understand the epidemiology of the vector-borne disease before undertaking any vaccine intervention.
"Before introduction of any new vaccine, you need to now the epidemiology of this disease or any disease. But, for dengue, we realised we do not have any. And, so this nationwide prevalence survey would be taken up," Director General of ICMR Soumya Swaminathan said.
She was speaking at an MoU signing function here as part of which the Indian Council of Medical Research (ICMR) and Monash University of Australia will conduct laboratory trials on a global vector-control method, whereby a naturally occurring bacteria (Wolbachia) is introduced into dengue virus-carrying mosquitoes to "inhibit" viral transmission.
"National Institute of Epidemiology (NIE) in Chennai will be doing it and it would be a comprehensive one. So, it will take 1-2 years. We will begin in 2-3 months," Swaminathan, also Secretary of Department of Health Research, said.
Epidemiology is the study and analysis of the patterns, causes, and effects of health and disease conditions in defined populations.
A global pharmaceutical major has come up with a vaccine on dengue but it has not been introduced in India.
"That vaccine is like a booster vaccine, which means, it works if one has already got dengue infection. We need to know how many people have dengue anti-bodies...And where can we introduce the vaccine. So, before undertaking any vaccine intervention, we need to understand its epidemiology.
"We need to understand its epidemiology on various parameters, rural or urban or peri-urban. Also, geography-wise, north or south. But, by the end of the survey, we will have a good data. A comprehensive demographic profile on dengue epidemiology," the ICMR DG said.
Swaminathan said that besides dengue prevalence survey, the government is also planning a survey to understand the disease burden of hepatitis-B and hepatitis-C.
"For treatment of hepatitis-B and hepatitis-C, we need to know the disease burden, before undertaking any intervention. Hepatitis-A is water-borne but the other two are contracted through injection or sexually transmitted.
"Our priority would be hepatitis-B and hepatitis-C as we limited dry blood spots. So, hepatitis-A burden study would eb considered accordingly," she said, adding that it would be done through National Family Health Survey.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 07 2017 | 9:28 PM IST

Next Story